company background image
KHTR.F logo

Knight Therapeutics OTCPK:KHTR.F Stock Report

Last Price

US$4.32

Market Cap

US$418.2m

7D

14.0%

1Y

8.3%

Updated

17 Mar, 2025

Data

Company Financials +

Knight Therapeutics Inc.

OTCPK:KHTR.F Stock Report

Market Cap: US$418.2m

KHTR.F Stock Overview

Operates as a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceutical products in Canada and Latin America. More details

KHTR.F fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Knight Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Knight Therapeutics
Historical stock prices
Current Share PriceCA$4.32
52 Week HighCA$4.55
52 Week LowCA$3.48
Beta0.42
1 Month Change8.62%
3 Month Change15.82%
1 Year Change8.27%
3 Year Change-2.92%
5 Year Change25.58%
Change since IPO-21.91%

Recent News & Updates

Recent updates

Shareholder Returns

KHTR.FUS PharmaceuticalsUS Market
7D14.0%-1.4%1.7%
1Y8.3%1.0%10.0%

Return vs Industry: KHTR.F exceeded the US Pharmaceuticals industry which returned -0.1% over the past year.

Return vs Market: KHTR.F matched the US Market which returned 9% over the past year.

Price Volatility

Is KHTR.F's price volatile compared to industry and market?
KHTR.F volatility
KHTR.F Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement6.5%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.4%

Stable Share Price: KHTR.F has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: KHTR.F's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014725Samira Sakhiawww.knighttx.com

Knight Therapeutics Inc. operates as a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceutical products in Canada and Latin America. The company was founded in 2014 and is based in Montreal, Canada. It operates in additional locations in Latin America, such as Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, and Uruguay.

Knight Therapeutics Inc. Fundamentals Summary

How do Knight Therapeutics's earnings and revenue compare to its market cap?
KHTR.F fundamental statistics
Market capUS$418.18m
Earnings (TTM)-US$21.51m
Revenue (TTM)US$244.09m

1.8x

P/S Ratio

-20.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KHTR.F income statement (TTM)
RevenueCA$348.64m
Cost of RevenueCA$180.37m
Gross ProfitCA$168.27m
Other ExpensesCA$199.00m
Earnings-CA$30.73m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 20, 2025

Earnings per share (EPS)-0.31
Gross Margin48.26%
Net Profit Margin-8.81%
Debt/Equity Ratio6.7%

How did KHTR.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 15:46
End of Day Share Price 2025/03/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Knight Therapeutics Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David KideckelBeacon Securities Limited
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity